In this randomized, multicentered study, 157 males and 130 females with laboratory-confirmed, uncomplicated anogenital Neisseria gonorrhoeae infections were evaluated to determine the efficacy and safety of a single 300-mg oral dose of rosoxacin versus 3.5 g of ampicillin plus 1 g of probenecid. A total of 130 males and 101 females were evaluated. Rosoxacin cured 90.3% (P = 0.053) and 94.1% (P = 0.62), respectively, whereas ampicillin was effective in 98.5 and 98% of males and females, respectively. All 39 patients with anorectal infections were cured. One penicillinase-producing N. gonorrhoeae strain was isolated and was eradicated with rosoxacin. Of 212 pretreatment isolates tested, 201 were inhibited by 0.06 ,ug or less of rosoxacin per ml. The MICs of rosoxacin for the remaining 11 isolates ranged up to 0.5 pLg/ml. A computer-generated balance randomization chart for men and women was provided to each center. Patients were assigned, in order of entry, to receive either a single 300-mg oral dose of rosoxacin or 3.5 g of ampicillin plus 1 g of probenecid. The trial was not double blind. Cure was defined as negative cultures for N. gonorrhoeae 3 to 8 days after treatment.
The incidence of adverse effects was relatively high (29% for the rosoxacin group versus 18% for the ampicillin group), but none of the reactions required medical intervention nor did they result in serious sequelae.
Rosoxacin is a novel quinolone derivative chemically related to nalidixic acid. It is active in vivo and in vitro against most gram-negative pathogens including Neisseria gonorrhoeae. The MIC of rosoxacin for ,3-lactamase-positive and -negative strains of N. gonorrhoeae is -0.125 p.g/ml (4, 8) . The pharmacokinetics of this drug make it favorable for treating gonorrhea: a single 300-mg oral dose achieves a peak serum concentration of 5 ,ug/ml at 2.5 h, with a half-life of 4 h (J. R. O'Conner, R. A. Dobson, P. E. Came, and R. B. Wagner, Program Abstr. Intersci. Conf. Antimicrob. Agents Chemother. 19th, Boston, Mass., abstr. no. 511, 1979) .
These properties suggest that rosoxacin may offer an alternative single-dose therapy for uncomplicated gonorrhea due to both non-penicillinase-and penicillinase-producing strains. Rosoxacin as single oral doses of 300 and 200 mg has been used successfully in 28 of 28 males and 87 of 87 females infected with genital or anorectal penicillinase-producing (PP) N. gonorrhoeae in the Philippines, Indonesia, Kenya (9) .
A computer-generated balance randomization chart for men and women was provided to each center. Patients were assigned, in order of entry, to receive either a single 300-mg oral dose of rosoxacin or 3.5 g of ampicillin plus 1 g of probenecid. The trial was not double blind. Cure was defined as negative cultures for N. gonorrhoeae 3 to 8 days after treatment.
To assess drug toxicity pre-and posttreatment, we carried out complete blood counts, platelet counts, a multichannel 12 biochemical screen, and urinalysis. Adverse reactions were determined by direct questioning at the follow-up visit and were classified by their effect on the central nervous system (CNS), gastrointestinal (GI) system, or other body system. CNS dysfunction included dizziness, drowsiness, headache, euphoria, and altered visual perception whereas GI adverse effects included diarrhea, nausea, or vomiting.
The Cochrane-Mantel-Haenszel mean score test was applied to the data, and no statistically significant differences were demonstrated between study centers; therefore, all data were pooled for final evaluation. The Fisher exact test was used to examine differences in responses between ANTIMICROB. AGENTS CHEMOTHER. Overall, 29% of rosoxacin-treated patients and 18% of ampicillin-plus-probenecid-treated patients developed adverse effects (Table 3) . None of the reactions required medical intervention nor did they result in any serious sequelae. CNS side effects occurred in 31% of females and 28% of males treated with rosoxacin compared with 2% of females and 5% of males, receiving ampicillin plus probenecid. Dizziness was the commonest reaction reported. Six rosoxacin reactions were classified as severe by the patient. Onset occurred 20 min to 4 h after administration of the drug, with the nmean duration of symptoms being 5 h (range, 2 min to 72 h). The difference in CNS side effects experienied by the rosoxacin and ampicillin plus probenecid groups is highly statistically significant (P < 0.001).
GI disturbances occurred in 5% of females and 4% of males treated with rosoxacin, whereas 11% of females and 15% of males receiving ampicillin plus probenecid reported GI adverse effects. Two men administered ampicillin plus probenecid reported their reaction as severe. The time of onset of GI side effects after administration of ampicillin plus probenecid was generally >4 h with a mean duration of 28 h (range, 30 min to 6 days). The difference in GI side effects observed in the rosoxacin and ampicillin plus probenecid groups is statistically significant (0.05 > P > 0.02). Howev The high incidence of adverse effects may be partially explained by their subjective nature, taking into account that patients were forewarned about their nature and then directly questioned on adverse effects. The incidence of rosoxacin CNS-related side effects was high; however, they were of short duration, tended to be mild, and cleared without sequelae. The GI side effects from ampicillin plus probenecid were of much longer duration although they also cleared without medical intervention.
Unfortunately, although rosoxacin is active in vitro against both Chlamydia trachomatis and Ureaplasma urealyticum when administered as single-dose therapy, it is not effective in eradicating coexisting genital infection with C.
trachomatis (5) .
